91.38 <%= Resources.Global.txtUp %>
Updated 16:40:00
Change % 1.17% Stock price increasing
Change 1.06 Stock price increasing
Volume 448,717
High 92.58
Low 89.40
Open 91.10
ISIN BE0003818359
Prev close 90.32
# of shares 54.43M
Market cap 4,974.23M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  91.38 -2.9% Stock price decreasing 4.8% Stock price increasing 1.6% Stock price increasing 12.7% Stock price increasing 17.5% Stock price increasing
Powered by TradingView

News about Galapagos

  • English
  • Regulatory news

Company profile

Galapagos is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
16 November 2018 20:45:26
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181114.1 - EUROWEB3 - 2018-11-16 21:45:26 - 2018-11-16 20:45:26 - 1000 - Website: OKAY